Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 377

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

Castro, Elena, Romero-Laorden, Nuria, del Pozo, Angela, Lozano, Rebeca, Medina, Ana, Puente, Javier, Piulats, Josep Maria, Lorente, David, Saez, Maria Isabel, Morales-Barrera, Rafael, Gonzalez-Billalabeitia, Enrique, Cendón, Ylenia, García-Carbonero, Iciar, Borrega, Pablo, Mendez Vidal, M. José, Montesa, Alvaro, Nombela, Paz, Fernández-Parra, Eva, Gonzalez del Alba, Aránzazu, Villa-Guzmán, José Carlos, Ibáñez, Kristina, Rodriguez-Vida, Alejo, Magraner-Pardo, Lorena, Perez-Valderrama, Begoña, Vallespín, Elena, Gallardo, Enrique, Vazquez, Sergio, Pritchard, Colin C., Lapunzina, Pablo, Olmos, David·2019·Journal of Clinical Oncology

Abstract

Purpose: Germline mutations in DNA damage repair (DDR) genes are identified in a significant proportion of patients with metastatic prostate cancer, but the clinical implications of these genes remain unclear. This prospective multicenter cohort study evaluated the prevalence and effect of germline DDR (gDDR) mutations on metastatic castration-resistance prostate cancer (mCRPC) outcomes. Patients and Methods: Unselected patients were enrolled at diagnosis of mCRPC and were screened for gDDR mutations in 107 genes. The primary aim was to assess the impact of ATM/BRCA1/BRCA2/ PALB2 germline mutations on cause-specific survival (CSS) from diagnosis of mCRPC. Secondary aims included the association of gDDR subgroups with response outcomes for mCRPC treatments. Combined progression-free survival from the first systemic therapy (PFS) until progression on the second systemic therapy (PFS2) was also explored. Results: We identified 68 carriers (16.2%) of 419 eligible patients, including 14 with BRCA2, eight with ATM, four with BRCA1, and none with PALB2 mutations. The study did not reach its primary end point, because the difference in CSS between ATM/BRCA1/BRCA2/PALB2 carriers and noncarriers was not statistically significant (23.3 v 33.2 months; P = .264). CSS was halved in germline BRCA2 (g BRCA2) carriers (17.4 v 33.2 months; P = .027), and g BRCA2 mutations were identified as an independent prognostic factor for CCS (hazard ratio [HR], 2.11; P = .033). Significant interactions between g BRCA2 status and treatment type (androgen signaling inhibitor v taxane therapy) were observed (CSS adjusted P = .014; PFS2 adjusted P = .005). CSS (24.0 v 17.0 months) and PFS2 (18.9 v 8.6 months) were greater in g BRCA2 carriers treated in first line with abiraterone or enzalutamide compared with taxanes. Clinical outcomes did not differ by treatment type in noncarriers. Conclusion: g BRCA2 mutations have a deleterious impact on mCRPC outcomes that may be affected by the first line of treatment used. Determination of g BRCA2 status may be of assistance for the selection of the initial treatment in mCRPC. Nonetheless, confirmatory studies are required before these results can support a change in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.18.00358

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 377

Metadata

Authors
Castro, E., Romero-Laorden, N., del Pozo, A., Lozano, R., Medina, A., Puente, J., Piulats, J. M., Lorente, D., Saez, M. I., Morales-Barrera, R., Gonzalez-Billalabeitia, E., Cendón, Y., García-Carbonero, I., Borrega, P., Mendez Vidal, M. J., Montesa, A., Nombela, P., Fernández-Parra, E., Gonzalez del Alba, A., Villa-Guzmán, J. C., Ibáñez, K., Rodriguez-Vida, A., Magraner-Pardo, L., Perez-Valderrama, B., Vallespín, E., Gallardo, E., Vazquez, S., Pritchard, C. C., Lapunzina, P., & Olmos, D.
Venue
Journal of Clinical Oncology
Published
2019-02-20
Volume
37
Issue
6
Pages
490-503
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2908857416
Cited by
377
References
35
FWCI
32.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.18.00358
The paper
Castro, E., Romero-Laorden, N., del Pozo, A., Lozano, R., Medina, A., Puente, J., Piulats, J. M., Lorente, D., Saez, M. I., Morales-Barrera, R., Gonzalez-Billalabeitia, E., Cendón, Y., García-Carbonero, I., Borrega, P., Mendez Vidal, M. J., Montesa, A., Nombela, P., Fernández-Parra, E., Gonzalez del Alba, A., . . . Olmos, D. (2019). PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.00358

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.